Stonebridge Capital Management Inc. Makes New $779,000 Investment in Bristol Myers Squibb Company $BMY

Posted by Stanley Muller on Aug 27th, 2026

Stonebridge Capital Management Inc. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 13,525 shares of the biopharmaceutical company’s stock, valued at approximately $779,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $27,000. Swiss RE Ltd. purchased a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Addison Advisors LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth approximately $32,000. Finally, Bayban purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $31,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Jefferies Financial Group lowered Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued an “overweight” rating on the stock. Royal Bank Of Canada boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Truist Financial reissued a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Guggenheim reiterated a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and an average price target of $66.06.

View Our Latest Stock Report on Bristol Myers Squibb

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Trading Down 0.4%

Shares of BMY stock opened at $67.68 on Thursday. The business has a 50-day moving average of $61.25 and a 200 day moving average of $59.60. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The stock has a market capitalization of $138.25 billion, a PE ratio of 14.91, a P/E/G ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 earnings per share. The business’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.